1. Resistance not limited to P. acnes
Researchers reviewed studies on the use of antibiotics in acne vulgaris
over nearly a 50-year period and found that both correct and incorrect use of antibiotics for acne
can promote antimicrobial resistance. Among factors contributing to this resistance are antibiotic
monotherapy, long-term administration of antibiotics, and the administration of antibiotics without
concurrent benzoyl peroxide and/or topical retinoids. The authors concluded that antibiotics should
be prescribed in combination with benzoyl peroxide and/or topical retinoids and be limited to a
maximum of several months. (J Drugs Dermatol. 9(6):655-64)
2. Prescribing habits are changing in response to resistance..
Prescribing habits are changing due to resistance concerns,
one recent study suggests. Investigators examined the National Ambulatory Medical Care Survey database
for acne patients and noted declines in the use of erythromycin and isotretinoin for acne among
all physicians, and increases in use of tetracyclines. BPO monotherapy decreased among dermatologists
but not other clinicians. Use of BPO/clindamycin combination topical treatments increased among all
clinicians. Topical retinoid use increased among dermatologists but appeared to be on the decline
among non-dermatologists. (J Drugs Dermatol. 9(5):519-24.)
3. “Antifungals” may offer new options.
According to a new study, antifungal agents may offer an alternative to
antibiotics to combat P. acnes. Of the five agents tested in vivo against P. acnes isolated from patients
with acne, miconazole, ketoconazole, and itraconazole showed concentration-dependent anti-P. acnes
activity, including against antibiotic-resistant isolates, while fluconazole and voriconazole showed no
anti-P. acnes activity. (Biol Pharm Bull. 33(1):125-7.)
4. BPO wash alone may not reduce P. acnes counts
Benzoyl peroxide (BPO 5.3%) emollient foam may be more
effective than BPO (8%) wash in reducing P. acnes levels on the back. Twenty patients colonized
with P. acnes on their backs were treated once daily with BPO foam for two weeks; no treatment in
week 3; and BPO wash alone once daily for two more weeks. Results showed that total P. acnes
counts were reduced by 1.9-log (one week) and 2.1-log (two weeks) with BPO emollient foam, while
BP wash did not reduce P. acnes counts after two weeks. (J Drugs Dermatol. 9(6):622-5.)
5. New compounds are in the pipeline.
Lauric acid (LA) is among potential agents on the horizon to counter P.
acnes. A new study found that LA-loaded liposomes (LipoLA) could fuse with the membranes of P.
acnes and release the carried LA directly into the bacterial membranes, thereby killing the bacteria
effectively. Since LA is a natural compound that is the main acid in coconut oil and also resides in
human breast milk and liposomes have been successfully and widely applied as a drug delivery
vehicle in the clinic, the authors suggested that LipoLA may be a safe and effective medication for
acne vulgaris. (Biomaterials. 30(30):6035-40.)
